Covishield comprises over 90% of 127.6 mn Covid vaccines given so far

India started the rollout on January 16

Covishield
Covishield coronavirus vaccine | Photo: PTI
Press Trust of India New Delhi
2 min read Last Updated : Apr 21 2021 | 2:02 PM IST

Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 127.6 million COVID-19 vaccines administered across the country so far, according to government data on Wednesday.

Of this, 15 states and union territories have only given Covishield, being manufactured by the Pune-based Serum Instiute of India. The other vaccine being administered in India is the indigenous Covaxin from Bharat Biotech in Hyderabad.

Giving details, of the 127,605,870 COVID-19 vaccination jabs administered till now, 11,60,65,107 are of Covishield while 1,15,40,763 are of Covaxin, according to the government's CO-WIN portal.

Moreover, about 15 states and union territories, including Goa, Chandigarh and Jammu and Kashmir, have administered only Covishield to its beneficiaries.

Experts said Covishield is being produced at a much higher scale than Covaxin due to which its availability is more.

Dr Samiran Panda, the Head of Epidemiology and Communicable Diseases at the Indian Council of Medical Research, said soon the production of Covaxin will be ramped up.

"Following which, the vaccine production capacity will increase significantly," he said.

Bharat Biotech on Tuesday said capacity expansion has been implemented across multiple facilities in Hyderabad and Bangalore, to reach approximately 700 million doses per year.

The Department of Biotechnology is also providing financial support as grants to vaccine manufacturing facilities for enhanced production capacities.

"The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021 i.e increasing the production from 10 million vaccine doses in April, 2021 to 60-70 million vaccine dose per month in July-August," said the ministry of science and technology in a statement on Monday.

India granted emergency use authorisation to Covaxin and Covishield, following which the vaccination drive started in the country on January 16.

Prime Minister Narendra Modi and External Affairs Minister S Jaishankar were among those administered Bharat Biotech's Covaxin.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Apr 21 2021 | 1:56 PM IST

Next Story